2,706 results match your criteria Pharmacogenomics [Journal]


Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing 400042, PR China.

Aim: This study was conducted to investigate the relationship between ABCB1 gene C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients.

Methods: Seven electronic databases (PubMed, EMBASE, Web of Science, Cochrane, OVID, Chinese biomedical literature [CBM], China National Knowledge Infrastructure [CNKI] and Wanfang databases) were searched to select eligible publications until 18 July 2018. The references of relevant articles were also manually searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0172DOI Listing
April 2019
1 Read

A drug response predictor to guide treatment for breast cancer.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Oncology Venture, Hørsholm, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0195DOI Listing
April 2019
1 Read

Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Molecular Immunopathology & Histocompatibility Unit, Onassis Cardiac Surgery Center, Athens, Greece.

Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the CYP2C9 and the VKORC1 gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0189DOI Listing
April 2019
1 Read

Implementing pharmacogenetic testing in rural primary care practices: a pilot feasibility study.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Mission Health, Mission Research Institute, Asheville, NC 28801, USA.

Aim: Assess feasibility and perspectives of pharmacogenetic testing/PGx in rural, primary care physician (PCP) practices when PCPs are trained to interpret/apply results and testing costs are covered.

Methods: Participants included PCPs who agreed to training, surveys and interviews and eligible patients who agreed to surveys and testing. 51 patients from three practices participated. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0200
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0200DOI Listing
April 2019
1 Read

Cell-free DNA diagnostics: current and emerging applications in oncology.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Department of Pathology & Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.

Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulating tumor DNA mutations versus primary tumor mutations. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0174
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0174DOI Listing
April 2019
1 Read

CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Department of Neuropsychology, Sanford Health, Fargo, ND 58122, USA.

Aim: To examine the impact of CYP2C19 genotype on selective serotonin reuptake inhibitor (SSRI) prescribing patterns. Patients & methods: Observational cohort containing 507 unique individuals receiving an SSRI prescription with CYP2C19 genotype already in their electronic medical record. Genotype was distributed as follows: n = 360 (71%) had no loss of function alleles, 136 (26. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0156DOI Listing

Genomics of radiation sensitivity in squamous cell carcinomas.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Division of Surgical Oncology, National Cancer Centre, 11 Hospital Drive, 169610, Singapore.

Radiotherapy is an important modality in the management of squamous cell cancers with 50% of patients receiving radiotherapy at some point. Despite technological advances, the risk of severe toxicity in a proportion of radiosensitive patients limits radiation doses that can be safely prescribed affecting the potential for cure. While comorbidities, lifestyle and treatment factors can influence interindividual variations, genetic factors are thought to play a major role, accounting for approximately 80% of the variance observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0154DOI Listing
April 2019
1 Read

Perplexed by PGx? Exploring the impact of pharmacogenomic results on medical management, disclosures and patient behavior.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Medcan Health Management, Inc., Toronto, Ontario, Canada.

Pharmacogenomic (PGx) tests represent significant advances in precision medicine. Our aim was to explore perceptions following the return of PGx results, medication management, and disclosure to providers. We surveyed clients who had PGx testing and conducted a chart review of PGx results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0179DOI Listing

Identification of a single nucleotide polymorphism within CDH2 gene associated with bone morbidity in childhood acute lymphoblastic leukemia survivors.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Sainte-Justine University Hospital Research Centre, Montreal, Quebec, H3T 1C5, Canada.

Aim: To identify genetic markers associated with late treatment-related skeletal morbidity in survivors of childhood acute lymphoblastic leukemia (ALL).

Patients & Methods: To this end, we measured the association between reduction in bone mineral density or vertebral fractures prevalence and variants from 1039 genes derived through whole exome sequencing in 242 childhood ALL survivors. Top-ranking variants were confirmed through genotyping, and further explored with stratified analyses and multivariable models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0169DOI Listing
April 2019
1 Read

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA.

Aim: This study evaluated the impact of CYP3A5 genotype and other patient characteristics on sublingual (SL) tacrolimus exposure and compared the relationship with oral administration.

Patients & Methods: Tacrolimus concentrations were retrospectively collected for adult lung transplant recipients, who were genotyped for CYP3A5*3, CYP3A4*22, CYP3A7*1C, and POR*28. Regression analyses were performed to determine covariates that impacted the SL and oral tacrolimus concentration/dose ratios. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2019-0002
Publisher Site
http://dx.doi.org/10.2217/pgs-2019-0002DOI Listing
April 2019
2 Reads

VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence.

Pharmacogenomics 2019 Apr 15. Epub 2019 Apr 15.

Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.

Aim: To determine if selected serotonergic and noradrenergic gene variants are associated with heroin addiction.

Subjects & Methods: A total of 126 variants in 19 genes in subjects with Dutch European ancestry from The Netherlands. Subjects included 281 opioid-dependent volunteers in methadone maintenance or heroin-assisted treatment, 163 opioid-exposed but not opioid-dependent volunteers who have been using illicit opioids but never became opioid-dependent and 153 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0137DOI Listing
April 2019
1 Read

A systematic review of genome-wide association studies of antipsychotic response.

Pharmacogenomics 2019 Mar 18;20(4):291-306. Epub 2019 Mar 18.

Department of Experimental & Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.

Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0163DOI Listing
March 2019
1 Read

Contemporary pharmacogenetic assays in view of the PharmGKB database.

Pharmacogenomics 2019 Mar 18;20(4):261-272. Epub 2019 Mar 18.

Laboratory of Pharmaceutical Biotechnology, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.

Aim:  Six modern PGx assays were compared with the Pharmacogenomics Knowledge Base (PharmGKB) to determine the proportion of the currently known PGx genotypes that are assessed by these assays.

Materials & Methods: Investigated assays were 'Ion AmpliSeq Pharmacogenomics', 'iPLEX PGx Pro', 'DMET Plus,' 'PharmcoScan,' 'Living DNA' and '23andMe.'

Results: PharmGKB contains 3474 clinical annotations of which 75, 70 and 45% can be determined by PharmacoScan, Living DNA and 23andMe, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0167DOI Listing

GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients.

Pharmacogenomics 2019 Mar 18;20(4):273-277. Epub 2019 Mar 18.

Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, PR China.

Aim: Exenatide is a glucagon-like peptide 1receptor agonist, having both glycemic and weight loss benefits. Given that previous pharmacogenetic studies reported inconsistent evidence of association between variants in the drug target gene GLP1R and response to exenatide, we set out to examine two common coding variants Chinese population. Materials & methods: Here, we recruited 285 overweight Type 2 diabetes patients from China and investigated the association between two common missense variants and response to exenatide, using multivariate linear model with adjustment for baseline and other covariates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0159DOI Listing

Differential long noncoding RNAs expression in cancer-associated fibroblasts of non-small-cell lung cancer.

Pharmacogenomics 2019 Feb 27;20(3):143-153. Epub 2019 Feb 27.

Department of Pharmacology, School of Pharmacy, Guangxi Medical University, Nanning 530021, Guangxi, PR China.

Aim: The aim of this study was to investigate the role of long noncoding RNAs (lncRNAs) profiles in cancer-associated fibroblasts (CAFs) during non-small-cell lung cancer (NSCLC) progression.

Materials & Methods: Differentially expressed lncRNAs and mRNAs were detected by lncRNA microarray between three patient-paired CAFs and the adjacent normal fibroblasts, which were obtained from tumoral and nontumoral portions of surgically resected lung tissue from three primary NSCLCs. Bioinformatic analyses including gene ontology and pathway analysis were applied to these differentially expressed mRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0102DOI Listing
February 2019
1 Read

The future of pharmacogenetics in the treatment of hypertension.

Pharmacogenomics 2019 Feb 27;20(3):129-132. Epub 2019 Feb 27.

Section of Nephrology, University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0191DOI Listing
February 2019
1 Read

The interleukin-17 G-197A polymorphism is associated with cyclosporine metabolism and transplant rejection in liver transplant recipients.

Pharmacogenomics 2019 Feb 25. Epub 2019 Feb 25.

Department of Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

Aim:  This study aimed to investigate the effect of and mechanism involved in the IL-17 SNP on cyclosporine metabolism and outcomes of liver transplantation (LT).

Materials & Methods:  The IL-17 genotype, IL-17 expression, postoperative outcome and cyclosporine concentration were reviewed in 106 LT recipients. The functional relevance of rs2275913 was evaluated by luciferase assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0198DOI Listing
February 2019

Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.

Pharmacogenomics 2019 Feb 20. Epub 2019 Feb 20.

Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions.

Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126).

Result: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0205DOI Listing
February 2019
5 Reads

Evaluation of the predictive performance of Bayesian dosing for warfarin in Chinese patients.

Pharmacogenomics 2019 Feb 19;20(3):167-177. Epub 2019 Feb 19.

Department of Neurology, Gongli Hospital, The Second Military Medical University, 219 Miaopu Road, Shanghai 200135, PR China.

Aim: To evaluate the accuracy and predictive performance of Bayesian dosing for warfarin in Chinese patients.

Materials & Methods: Six multiple linear regression algorithms (Wei, Lou, Miao, Huang, Gage and IWPC) and a Bayesian method implemented in Warfarin Dose Calculator were compared with each other.

Results: Six multiple linear regression warfarin dosing algorithms had similar predictive ability, except Miao and Lou. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0127DOI Listing
February 2019

Genome-wide association studies of therapeutic response: addressing the complexities.

Pharmacogenomics 2019 Mar 15;20(4):213-216. Epub 2019 Feb 15.

Leeds Institute for Data Analytics, School of Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0204DOI Listing

Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.

Pharmacogenomics 2019 Mar 15;20(4):217-223. Epub 2019 Feb 15.

Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Aim: Treatment and prevention of mother-to-child transmission of HIV in pregnancy utilizes tenofovir (TFV) and emtricitabine (FTC) as NRTI backbone in combination with a third agent from a different class. We hypothesized that combined effect of pregnancy and pharmacogenetics significantly changes TFV and FTC pharmacokinetics (PK). Therefore, this study aims to evaluate the role of SNPs of transporters (ABCC2 and ABCC4) on TFV and FTC PK during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0111DOI Listing
March 2019
3.218 Impact Factor

Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.

Pharmacogenomics 2019 Mar 15;20(4):251-260. Epub 2019 Feb 15.

Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.

Aim: This study aimed to establish a population pharmacokinetic (PPK) model in Chinese patients with chronic myeloid leukemia, and to quantify the effects of pharmacogenetics on pharmacokinetic parameters of imatinib.

Methods: A total of 229 plasma concentrations from 170 patients were analyzed. Nonlinear mixed effect model was used to establish the PPK model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0139DOI Listing

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Pharmacogenomics 2019 Mar 15;20(4):279-290. Epub 2019 Feb 15.

MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK.

Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0188DOI Listing
March 2019
1 Read

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Pharmacogenomics 2019 Mar 15;20(4):225-240. Epub 2019 Feb 15.

Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.

Aim: We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin.

Materials & Methods: Genotypes for SLCO1B1, NAT2, PXR, ABCB1 and UGT1A genes were determined using a TaqMan Genotyping OpenArray™. Nonlinear mixed-effects models were used to describe drug pharmacokinetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0166DOI Listing
March 2019
5 Reads
3.218 Impact Factor

Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer.

Pharmacogenomics 2019 Feb 8. Epub 2019 Feb 8.

Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

Aim: The aim of this study was to identify pharmacogenomic biomarkers to predict tegafur-uracil (UFT)-induced liver dysfunction.

Patients & Methods:  A total of 68 patients, who were administered UFT, were evaluated using a two-step pharmacogenomics analysis.

Results: The first screening revealed the association between five SNPs and UFT-induced hepatic dysfunction. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0100
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0100DOI Listing
February 2019
15 Reads

Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach.

Pharmacogenomics 2019 Jan 6;20(1):21-35. Epub 2018 Dec 6.

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, No. 1277, Jie Fang Road, Wuhan, Hubei province, 430022, PR China.

Aim: The aim of this study was to evaluate tacrolimus population pharmacokinetics and investigate factors that explain tacrolimus variability in adult heart transplant patients.

Methods: A total of 707 tacrolimus concentrations from 107 adult heart transplant patients were included in model development. The effects of demographic, clinical factors and CYP3A5 genotype on tacrolimus clearance were evaluated using a nonlinear mixed-effects modeling. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0116
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0116DOI Listing
January 2019
7 Reads

Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Pharmacogenomics 2019 Jan 6;20(1):9-20. Epub 2018 Dec 6.

Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Aim: To comprehensively interrogate CYP2D6 by integrating genotyping, copy number analysis and novel strategies to identify CYP2D6*36 and characterize CYP2D6 duplications.

Methods: Genotyping of 16 CYP2D6 alleles, multiplex ligation-dependent probe amplification (MLPA) and CYP2D6*36 and duplication allele-specific genotyping were performed on 427 African-American, Asian, Caucasian, Hispanic, and Ashkenazi Jewish individuals.

Results: A novel PCR strategy determined that almost half of all CYP2D6*10 (100C>T) alleles are actually *36 (isolated or in tandem with *10) and all identified duplication alleles were characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0135DOI Listing
January 2019
1 Read

Foreword: the year at Pharmacogenomics.

Authors:
Sarah Jones

Pharmacogenomics 2019 Jan;20(1)

Commissioning Editor, Pharmacogenomics, Future Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0190DOI Listing
January 2019

Association of endothelin receptor type A rs5333 gene polymorphism with steroid response in Egyptian children with idiopathic nephrotic syndrome.

Pharmacogenomics 2019 Feb 23;20(3):133-141. Epub 2019 Jan 23.

Department of Medical Microbiology & Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Aim: To investigate ENDRA rs5333 gene polymorphism distribution in idiopathic nephrotic syndrome (INS) and to analyze their association with response to steroid therapy, and biochemical markers of INS.

Subjects & Methods: The PCR-restriction fragment length polymorphism was used to analyze ENDRA rs5333 polymorphism in 100 children with idiopathic nephrotic syndrom (INS) and 100 healthy children. Plasma endothelin-1 were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0175DOI Listing
February 2019
2 Reads

Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.

Pharmacogenomics 2019 Feb 23;20(3):179-188. Epub 2019 Jan 23.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China.

Aim: The present study aimed to assess the association between IGF2/H19 genetic variants and susceptibility to platinum-based chemotherapy in epithelial ovarian cancer (EOC).

Methods: A total of 43 platinum-resistant (PR) and 138 platinum-sensitive (PS) EOC patients were recruited in our study. 21 polymorphisms in IGF2/H19 locus were genotyped by Sequenom MassARRAY assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0153DOI Listing
February 2019
5 Reads

Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis.

Pharmacogenomics 2019 Feb 23;20(3):189-212. Epub 2019 Jan 23.

Department of Pharmacy, Peking University First Hospital, 6# Dahongluochang Street, Xicheng District, Beijing, 100034, PR China.

Aim: Genetic polymorphisms may influence the incidence of angiotensin-converting enzyme (ACE) inhibitor-induced cough. This study aims to investigate this association.

Methods: Ten electronic databases and PharmGKB were systematically searched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0157DOI Listing
February 2019
1 Read
3.218 Impact Factor

Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.

Pharmacogenomics 2019 Jan 10;20(2):105-111. Epub 2019 Jan 10.

Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

As antiretroviral therapy has become more accessible across the world and coformulations have improved patient compliance; the morbidity and mortality of HIV/AIDS has decreased. However, there is still a substantial gap in knowledge regarding the impact of genetic variation on the metabolism of and response to some of the most commonly prescribed antiretrovirals, including the nucleotide reverse transcriptase inhibitor tenofovir. While it has been scientifically established that tenofovir must be activated to be efficacious against HIV, the enzymes responsible for this activation have not been well characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0140DOI Listing
January 2019
1 Read

Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.

Pharmacogenomics 2019 Jan 10;20(2):85-93. Epub 2019 Jan 10.

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Aim: To study the performance of a clinical pharmacogenetic model for the prediction of nonresponse in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) in combination with other synthetic or biologic disease-modifying anti-rheumatic drugs . This prediction model includes gender, smoking status, rheumatoid factor positivity and four genetic variants in AMPD1 (rs17602729), ATIC (rs2372536), ITPA (rs1127354) and MTHFD1 (rs17850560).

Methods:  A total of 314 RA patients from three Dutch studies were retrospectively included. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0144
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0144DOI Listing
January 2019
12 Reads

Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

Pharmacogenomics 2019 Mar 10;20(4):241-249. Epub 2019 Jan 10.

Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, PR China.

Aim: To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China.

Materials & Methods: A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0138DOI Listing
March 2019
3 Reads
3.218 Impact Factor

NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p.

Pharmacogenomics 2019 Feb 13;20(3):155-165. Epub 2018 Dec 13.

Department of Biological Sciences & Technology, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.

Aim: NF1 loss confers chemoresistance in multiple cancers. However, the etiology remains largely unknown. Our study aimed to scrutinize the role of NF1 in chemoresistant ovarian cancer and its underlying mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0161DOI Listing
February 2019
4 Reads

Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.

Pharmacogenomics 2019 Jan 12;20(2):113-127. Epub 2018 Dec 12.

Department of Oncology, Faculty of Medicine & Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic.

Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatment resistance, represents a major opportunity, but also a challenge in further research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0073DOI Listing
January 2019
2 Reads

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.

Pharmacogenomics 2019 Jan 6;20(1):37-47. Epub 2018 Dec 6.

Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.

Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD).

Patients & Methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0142
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0142DOI Listing
January 2019
21 Reads

Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.

Pharmacogenomics 2019 Jan 6;20(2):75-83. Epub 2018 Dec 6.

Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Purpose: Although clopidogrel is the most widely used oral P2Y12 receptor antagonist, up to 10% of acute coronary syndrome patients treated with clopidogrel will experience a recurrent myocardial infarction and 2-3% will experience stent thrombosis within 1 year. The purpose of this research is to describe the prevalence of pharmacogene variants associated with clopidogrel responsiveness (CYP2C19, B4GALT2, ABCB1, PON1, CES1 and P2RY12) in Hispanic/Latino patients of diverse backgrounds.

Methods: Minor allele frequencies of nine variants from participants of Hispanic Community Health Study/Study of Latinos were compared between subpopulations as well as to continental ancestry references using z-test for independent proportions. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0148
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462835PMC
January 2019
14 Reads

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

Pharmacogenomics 2019 Jan 6;20(2):95-104. Epub 2018 Dec 6.

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA.

Aim:  First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0162
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0162DOI Listing
January 2019
19 Reads

Prolonged clonazepam-induced withdrawal symptoms in an NAT2 ultraslow acetylator.

Pharmacogenomics 2019 Jan 6;20(2):69-73. Epub 2018 Dec 6.

Department of Pediatrics, USF Health South Tampa Center for Advanced Healthcare, Tampa, FL 33606, USA.

Clonazepam undergoes nitroreduction to 7-amino-clonazepam via CYP3A4/5, followed by acetylation to 7-acetamido-clonazepam via NAT2 enzyme. While no pharmacological activity is attributed to the metabolites of clonazepam, 7-amino-clonazepam has some affinity for the benzodiazepine receptor as a partial agonist for the gamma aminobutyric acid-A receptor and can compete with clonazepam. Interindividual variability in the incidence of adverse events in patients may, in part, be attributable to differences in clonazepam metabolism. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0145
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0145DOI Listing
January 2019
21 Reads

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Pharmacogenomics 2019 Jan 6;20(1):49-68. Epub 2018 Dec 6.

Unit of Clinical Pharmacology & Pharmacogenetics, Department of Clinical & Experimental Medicine, University of Pisa, Italy.

Circulating tumor DNA, circulating tumor cells and tumor-related exosomes may offer new opportunities to provide insights into the biological and clinical characteristics of a neoplastic disease. They represent alternative routes for diagnostic and prognostic purposes, and for predicting and longitudinally monitoring response to treatment and disease progression. Hence, circulating biomarkers represent promising noninvasive tools in the scenario of pancreatic cancer, where neither molecular nor clinical predictors of treatment benefit have been identified yet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0149DOI Listing
January 2019
4 Reads

CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements.

Pharmacogenomics 2019 Jan 6;20(1):3-8. Epub 2018 Dec 6.

Department of Pharmaceutical Sciences, School of Pharmacy, Medical Sciences Campus, University of Puerto Rico, San Juan, PR 00936, Puerto Rico.

Warfarin continues to be the mainstay therapy for preventing thrombus formation. Although pharmacogenetic algorithms have shown higher predictability of the optimal warfarin dose and lower occurrence of bleeding episodes, they often do not include ethno-specific genetic variants relevant to non-Europeans. This case report describes a rare missense variant at exon 9 of CYP2C9 (rs202201137; c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0143DOI Listing
January 2019
11 Reads

Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.

Pharmacogenomics 2018 Dec;19(18):1403-1412

Department of Genetics, Physic Anthropology & Animal Physiology, University of the Basque Country, UPV/EHU, Leioa, 48940, Spain.

Aim: Mucositis, linked to methotrexate, daunorubicin or cyclophosphamide, is a frequent childhood acute lymphoblastic leukemia (ALL) therapy side effect. miRNAs regulate the expression of pharmacokinetic/pharmacodynamic pathway genes. SNPs in miRNAs could affect their levels or function, and affect their pharmacokinetic/pharmacodynamic pathway target genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0113DOI Listing
December 2018
1 Read

Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.

Pharmacogenomics 2018 Dec 16;19(18):1383-1394. Epub 2018 Nov 16.

Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA.

Aim: This study tests whether polygenic risk scores (PRSs) for nicotine metabolism predict smoking behaviors in independent data.

Materials & Methods: Linear regression, logistic regression and survival analyses were used to analyze nicotine metabolism PRSs and nicotine metabolism, smoking quantity and smoking cessation.

Results: Nicotine metabolism PRSs based on two genome wide association studies (GWAS) meta-analyses significantly predicted nicotine metabolism biomarkers (R range: 9. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0081
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0081DOI Listing
December 2018
12 Reads

Genetic polymorphism contributes to I radiotherapy-induced toxicities in patients with differentiated thyroid cancer.

Pharmacogenomics 2018 Nov 16;19(17):1335-1344. Epub 2018 Oct 16.

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China.

Aim: To investigate the association between SNPs in DNA damage response pathways and toxicities following I radiotherapy of differentiated thyroid cancer (DTC). Materials & methods: We identified 22 functional SNPs of genes in DNA damage response pathways. MassArray was used to sequence SNP genotypes in 203 DTC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0070DOI Listing
November 2018
3 Reads

Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.

Pharmacogenomics 2018 Nov;19(16):1269-1284

Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, AB, AN T2N 1N4, Canada.

Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. Read More

View Article

Download full-text PDF

Source
https://www.researchgate.net/publication/24239584_Depression
Web Search
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0099
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0099DOI Listing
November 2018
13 Reads
3.220 Impact Factor

Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:
Jason H Karnes

Pharmacogenomics 2018 Dec 6;19(18):1413-1422. Epub 2018 Nov 6.

Department of Pharmacy Practice & Science, University of Arizona College of Pharmacy, Tucson, AZ 85721, USA.

Heparin-induced thrombocytopenia (HIT) is a life-threatening, immune-mediated adverse reaction to heparin anticoagulants. The inability to predict HIT represents a considerable liability associated with heparin administration. Genetic studies of HIT are challenging due to the scarcity of true HIT cases, potential for misclassification, and many environmental risk factors. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0147
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0147DOI Listing
December 2018
25 Reads

Pharmacogenetic relevance of endothelial nitric oxide synthase polymorphisms and gene interactions.

Pharmacogenomics 2018 Dec 6;19(18):1423-1435. Epub 2018 Nov 6.

Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo 14049-900, Brazil.

Endothelial nitric oxide synthase (NOS3) is a key enzyme responsible for nitric oxide (NO) generation in the vascular endothelium. Endothelial dysfunction is characterized by reduced NO production, and is a hallmark of cardiovascular diseases. Drugs with cardiovascular action may activate NOS3 and result in NO release and vasodilation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0098DOI Listing
December 2018
1 Read

Analysis of outpatient HER2 testing in New York state using the statewide planning and research cooperative system.

Pharmacogenomics 2018 Dec 6;19(18):1395-1401. Epub 2018 Nov 6.

Department of Pharmaceutical Sciences, The School of Pharmacy & Pharmaceutical Sciences, The State University of New York at Buffalo, 470, Kapoor Hall, Buffalo, NY 14214, USA.

Aim: HER2 testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib and neratinib. There is a paucity of reports describing the utilization rates of HER2 testing in large outpatient populations.

Methods: The Statewide Planning and Research Cooperative System (SPARCS) was used to examine HER2 testing across the state of New York (USA) during the 2012-2016 period. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0120
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0120DOI Listing
December 2018
6 Reads

Integrating metabolomics with genomics.

Authors:
Amalio Telenti

Pharmacogenomics 2018 Dec 6;19(18):1377-1381. Epub 2018 Nov 6.

Translational Institute & Department of Integrative Structural & Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs-2018-0155
Publisher Site
http://dx.doi.org/10.2217/pgs-2018-0155DOI Listing
December 2018
13 Reads